Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA accepts IND for clinical study of MR-301 for severe traumatic brain injury

Aug. 30, 2019

Pulmonary mucormycosis mouse model developed to test treatments

Aug. 30, 2019

Discovery of a targeted covalent CDK14 inhibitor with a TAIRE kinase-biased selectivity profile

Aug. 30, 2019

Novel Chemerin GPCR agonist OK-113 exhibits anti-inflammatory activity in DED mouse model

Aug. 30, 2019

OncoNano receives grant to support development of oncology product candidate ONM-500

Aug. 30, 2019

Neutrophils stick with dipeptidase in lung, liver

Aug. 30, 2019

Amyndas opens phase IIa study of AMY-101 in periodontal inflammation

Aug. 29, 2019

Phase III TULIP 2 trial of anifrolumab in SLE meets primary endpoint

Aug. 29, 2019

Acurx completes multiple-ascending-dose phase I study of ACX-362E for C. difficile infection

Aug. 29, 2019

European Commission approves Tecentriq for TNBC

Aug. 29, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...